A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever.
about
Animal models for Ebola and Marburg virus infectionsThe Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivoHuman fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosisCurrent ebola vaccinesA systematic screen of FDA-approved drugs for inhibitors of biological threat agentsFiloviral immune evasion mechanismsIntracellular events and cell fate in filovirus infectionFDA-approved selective estrogen receptor modulators inhibit Ebola virus infection.Adapted Lethality: What We Can Learn from Guinea Pig-Adapted Ebola Virus Infection ModelA Review of the Role of Food and the Food System in the Transmission and Spread of EbolavirusMouse models for filovirus infectionsDevelopment of a murine model for aerosolized ebolavirus infection using a panel of recombinant inbred miceInterferon-γ Inhibits Ebola Virus InfectionA screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity.Ebola virus can be effectively neutralized by antibody produced in natural human infection.The challenge of using experimental infectivity data in risk assessment for Ebola virus: why ecology may be important.A small nonhuman primate model for filovirus-induced diseasePathology of experimental aerosol Zaire ebolavirus infection in rhesus macaques.Identification of N-glycans from Ebola virus glycoproteins by matrix-assisted laser desorption/ionisation time-of-flight and negative ion electrospray tandem mass spectrometry.The Toll-Like Receptor 4 Antagonist Eritoran Protects Mice from Lethal Filovirus Challenge.The Ebola virus VP24 protein prevents hnRNP C1/C2 binding to karyopherin α1 and partially alters its nuclear import.Therapeutics for filovirus infection: traditional approaches and progress towards in silico drug design.Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence.Ebola virus. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment.Cathepsin B & L are not required for ebola virus replicationDNA vaccines for biodefense.Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy.An update on the use of antibodies against the filoviruses.Key genomic changes necessary for an in vivo lethal mouse marburgvirus variant selection process.Virus-like particles activate type I interferon pathways to facilitate post-exposure protection against Ebola virus infection.Hegemonic structure of basic, clinical and patented knowledge on Ebola research: a US army reductionist initiative.Evaluation of perceived threat differences posed by filovirus variants.Particle-to-PFU ratio of Ebola virus influences disease course and survival in cynomolgus macaques.The role of antigen-presenting cells in filoviral hemorrhagic fever: gaps in current knowledge.Bolstering Components of the Immune Response Compromised by Prior Exposure to Adenovirus: Guided Formulation Development for a Nasal Ebola VaccineLoss of Interleukin 1 Receptor Antagonist Enhances Susceptibility to Ebola Virus Infection.An animal model that reflects human disease: the common marmoset (Callithrix jacchus).Utility of Oral Swab Sampling for Ebola Virus Detection in Guinea Pig ModelPrediction and identification of mouse cytotoxic T lymphocyte epitopes in Ebola virus glycoproteins.Role of natural killer cells in innate protection against lethal ebola virus infection.
P2860
Q21131118-497FECAA-93C3-46C5-BD82-D210D6C22608Q21131393-BC41E3E0-4006-4B5F-BD73-9AFE6768917FQ21144780-4BD92533-D1E5-4CB2-8331-C34C246ECF17Q21534720-F98EDA89-0835-4797-8348-AA0DEDCC0FFCQ21559667-915300E5-E531-4549-A2E4-F0274808E893Q22305519-A5054051-F823-4A57-BB92-3C4299594ADFQ22305521-54075DC9-D06F-442C-9EC9-1ECB9EC5801CQ24568225-528DD138-31A3-4C2E-BF25-0D21EB1172DEQ26753858-A9962E7C-F497-4869-8274-571C05785F29Q26775108-619CAAAD-BABD-4AC5-9EB6-14894A0C799AQ27011569-DD36061B-7AD6-4118-8E58-17B02C416CC2Q27024113-3AD967E1-730F-4733-BACA-2902B36FFFD4Q28550929-506F67C8-24CF-4982-8545-AC8EF736E598Q30279239-B9E2AE48-CE99-456A-B319-E5801C852857Q30712477-2F4037CE-318E-4ECD-A338-6441A28C2E2BQ31007853-839CB48D-3CE5-4BE0-B4E6-C6DB665C4A6FQ33397400-8D7669A1-037E-4E7B-8EDA-33D55F0CBF5FQ33404944-ABDCC40D-CD91-4438-8678-2997DBA98336Q33529421-D714C2E5-B865-4A77-ACD0-2AD64B3635C1Q33603827-A11E820B-4273-4368-B183-DCEB57A7CC29Q34222991-453F95A8-5BED-414B-9CDA-F48B6BD929F3Q34371001-52FA7B51-FCF6-4E4D-B5FE-AACBEFB9D696Q34434866-4A9AB2E3-949A-4462-9089-7364296A511BQ34464824-0DF73A76-3FFA-4E84-A345-6FE8A211E0D0Q34511122-6D22E1FE-1B71-4F08-9E11-77C8C764F231Q34614260-067E2E51-BA9C-47F1-82C8-C41C921185D4Q34632946-F95B375F-3297-48C0-B3FC-BF77C38E840FQ34657170-C74D16ED-0B7F-42E8-B22C-8A036486DA5EQ35076563-8732FF94-97B9-4252-80A3-5F5CBB455152Q35125834-9795DE6D-AD44-4F96-A0FC-D3120C918936Q35595035-FE1BC07E-EECF-4D24-94F3-C65ACA42D593Q35601783-796354AD-1926-4F8A-8EBD-A6968967A674Q35745371-9E549C52-8937-4B48-ACEC-1CE10C40AE77Q35823426-1CB86B00-AA59-45C8-AD53-F33D7A3409D1Q35917496-2BF8179B-E38F-4557-AEB1-45F3CB7D74FDQ36043296-3578084F-8D8C-4175-BD68-ED06BEFE588DQ36045238-BF119455-9338-4DB4-B119-1E20E94618DEQ36121626-DF8FA452-FE35-490F-9FFA-3F8BF4706D45Q36138983-1A26D9FB-5167-4142-A777-CAF16E228980Q36399839-637F473A-AD06-4D6D-A680-FDDC3086FF9B
P2860
A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever.
@en
A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever.
@nl
type
label
A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever.
@en
A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever.
@nl
prefLabel
A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever.
@en
A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever.
@nl
P2093
P356
P1476
A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever.
@en
P2093
P304
P356
10.1086/514292
P407
P478
179 Suppl 1
P577
1999-02-01T00:00:00Z